Deferoxamine
(Redirected from Desferal)
Information about Deferoxamine[edit source]
Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload.
Liver safety of Deferoxamine[edit source]
Deferoxamine rarely causes serum aminotransferase elevations during therapy and has not been convincingly linked to instances of clinically apparent liver injury. == Mechanism of action of Deferoxamine == Deferoxamine (de” fer ox’ a meen) is parenterally administered iron chelating agent that binds iron with a high affinity and zinc and copper to a lesser extent. In clinical trials in patients with transfusion related iron overload, deferoxamine therapy lowered both circulating and tissue (cardiac, liver) iron levels and these reductions were maintained with long term subcutaneous infusions.
FDA approval information for Deferoxamine[edit source]
Deferoxamine was approved for use in the United States in 1968 and current indications are for patients with transfusion related chronic iron overload as well as for acute iron overdose or intoxication.
Dosage and administration for Deferoxamine[edit source]
Deferoxamine is available in vials of 500 and 2000 mg for intravenous, intramuscular or subcutaneous administration generically and under the brand name Desferal. The subcutaneous routine is used most often for chronic iron overload and the typical dose is 1000 to 2000 mg per day (20 to 40 mg/kg/day) for 5 to 7 days a week given by continuous infusion over 8 to 24 hours.
Side effects of Deferoxamine[edit source]
Side effects include injection site pain and infection, hypersensitivity reactions, arthralgias, myalgias, fever, headache, nausea and abdominal pain. Rare, but potentially severe adverse events of deferoxamine therapy include hearing and visual loss, acute renal failure and severe hypersensitivity reactions.
Arsenic Chelators
Copper Chelators (for Wilson Disease)
Iron Chelators
Lead Chelators
Mercury Chelators
| Deferoxamine Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
